Skip to main content
Top

25-09-2024 | Zolpidem | Adis Summary of Research

Adis Summary of Research: Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem

Author: Matt Shirley

Published in: Drugs & Therapy Perspectives

Login to get access

Abstract

The dual orexin receptor antagonist (DORA) daridorexant has been shown to improve objective sleep onset and maintenance in adults with insomnia disorder. This Adis Summary of Research summarises a report on an exploratory analysis that investigated the effect of daridorexant on the number, duration and distribution of night-time wake bouts, and their correlation with daytime functioning using data from two randomised controlled trials in adults with insomnia disorder.
Literature
1.
go back to reference Di Marco T, Scammell TE, Meinel M, et al. Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem. CNS Drugs. 2023;37(7):639–53.CrossRefPubMedPubMedCentral Di Marco T, Scammell TE, Meinel M, et al. Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem. CNS Drugs. 2023;37(7):639–53.CrossRefPubMedPubMedCentral
Metadata
Title
Adis Summary of Research: Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem
Author
Matt Shirley
Publication date
25-09-2024
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01107-3